Bookmark1. Median overall survival and progression-free survival were greater in the tebentafusp...
Read More
Bookmark1. In this retrospective study, the use of deep learning models improved the accuracy of...
Read More
Bookmark1. The CORE trial showed that a cardio-oncology rehabilitation program demonstrated...
Read More
Bookmark1 .The progression-free survival in berzosertib with topotecan vs topotecan alone was not...
Read More
Bookmark1. One-third of patients with a cancer signal were correctly diagnosed to have cancer. 2....
Read MoreBookmark1. In this cross-sectional study, there was a significant negative relationship between supportive care needs and spiritual well-being and between supportive care needs and psychological resilience in breast cancer...
Read More
Bookmark1. Median PFS was improved in the olaparib arm vs placebo, with an HR 0.57 in the BRCAm...
Read More
Bookmark1. The second greatest burden of lung cancer worldwide is attributed to squamous cell...
Read More
Bookmark1. Patients in the camrelizumab-rivoceranib group reported significantly greater...
Read More
Bookmark1. Patients with centrally located breast cancer (CLBC) had higher breast cancer-specific...
Read More
Bookmark1. Recurrence-free survival was significantly different between the adjuvant everolimus...
Read More
Bookmark1. Intracranial objective response rate was 42% in the BRAF V600 mutation-positive cohort...
Read More
Bookmark1. The GI-Genius neural network system did not improve the rate of detecting advanced...
Read More
Bookmark1. In this case-control study, younger age of onset of non-alcoholic fatty liver disease...
Read More
Bookmark1. The hazard ratio of skeletal-related events in patients treated with radiation compared...
Read More
Bookmark1. 5-year distant disease-free survival was comparable between both groups. 2. 5-year...
Read More
Bookmark1. The median OS was 13.2 months with TTFields arm vs 9.9 months with standard arm, with...
Read More
Bookmark1. This phase 2 randomized clinical trial found that patients with metastatic colorectal...
Read More
Bookmark1. Disease-free survival at 24 months was 84% in the nivolumab group compared to 73% in...
Read More
Bookmark1. 37% of study patients had an objective response to treatment with atezolizumab. 2....
Read More
